Latest News and Press Releases

BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed...

BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as...

Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism...

BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September...

Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual MeetingData suggest favorable...

JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present...

Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented...